THANK YOU FOR SUBSCRIBING
By utilising natural killer cells (NK cells) encapsulated within 3D-printed hydrogels, this innovative method shows promising potential in improving the viability and activity of NK cells, allowing them to effectively target and confront cancerous tissues.
FREMONT, CA: In the ongoing battle against cancer, medical researchers have achieved a groundbreaking milestone with the advent of 3D bioprinting technology. This innovation has opened new avenues for cancer treatment, promising a practical and personalized approach to eliminating cancer cells. By harnessing the potential of bioprinting, healthcare institutions and biotech organisations are revolutionizing the oncology landscape and offering patients a ray of hope in the fight against cancer.
The world's first three-dimensional (3D) bioprinting technology capable of eradicating cancer cells through the action of immune cells has been successfully created. This achievement involved incorporating natural killer (NK) cells within 3D-printed hydrogels, thus minimising the loss of NK cells and allowing a significant portion of these cells to target tumour cells effectively. The hydrogel develops pores through which viable NK cells are eventually released after a specific duration, enabling them to carry out their immune functions.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
NK cells have been commonly utilised for immunotherapy, but their effectiveness in clinical trials for solid tumours has been limited when administered through intravenous injection. The reason for this limitation is that NK cells struggle to maintain sufficient viability and are unable to effectively target solid tumours.
Conversely, with the aid of the recently developed technology, NK cells are injected into the hydrogel, which is subsequently 3D-printed and cultured in an optimal environment. This process significantly improves the viability and activity of NK cells, empowering them to effectively engage with cancerous tissues.
The Advancement of 3D Bioprinting
Conventional cancer treatments, like chemotherapy and radiation therapy, often cause debilitating side effects and have limited effectiveness due to their generalized nature. However, 3D bioprinting is revolutionizing cancer treatment by allowing the creation of patient-specific tissues and tumour models. This enables precise targeting of cancer cells while minimizing harm to healthy tissues.
Applications and Opportunities
Pharmaceutical Research and Drug Testing: Pharmaceutical organizations are leveraging 3D bioprinting technology to develop more targeted and efficient anti-cancer drugs. By using actual patient cells to create tumour models, drug testing becomes highly accurate and reliable, leading to a significant reduction in costly clinical trial failures. Biotech firms collaborate with these organizations to provide bioprinting services and tumour models for drug development purposes.
Medical Equipment and Consumables: The adoption of 3D bioprinting in cancer treatment necessitates the development of specialized medical equipment and consumables. Collaborations between bioprinting technology providers and medical equipment manufacturers lead to the creation of optimized bioprinters, bio-inks, and other ancillary products tailored for cancer research and treatment applications.
Hospital and Research Institute Partnerships: Hospitals and research institutions integrate 3D bioprinting labs into their existing infrastructure, fostering a patient-centric approach to cancer treatment. By collaborating with bioprinting technology organizations, medical institutions gain access to the latest advancements, ensuring cutting-edge and personalized care for their patients.
Bioprinting Service Providers: Dedicated organizations emerge as specialized service providers, offering 3D bioprinting solutions to research institutes, pharmaceutical organizations, and healthcare facilities. These service providers offer expertise in tissue engineering, bio-ink development, and patient-specific tumour modelling, making the technology more accessible to a broader audience.
3D bioprinting technology represents a remarkable advancement in the fight against cancer. Its potential to transform cancer treatment into a precise and personalised approach opens up endless opportunities for business collaborations. Through continued research, investment, and collaboration, the vision of conquering cancer with 3D bioprinting is on the horizon.
More in News